ReviewFrontiers in pharmacology2019
Comprehensive Review on Phytochemicals, Pharmacological and Clinical Potentials of
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.
- Pooled it
- Comparative Effects ofNutrients · 2024Trial
- The Effect of a 14-DayNutrients · 2022Trial
- Efficacy and Sustainability of Diabetes-Specific Meal Replacement on Obese and Overweight Type-2 Diabetes Mellitus Patients: Study Approaches for a Randomised Controlled Trial and Impact of COVID-19 on Trial Progress.International journal of environmental research and public health · 2022Trial
- Review
- Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus.Pharmaceutics · 2026Review
- Exploring the therapeutic potential ofFrontiers in pharmacology · 2026Article
- Article
- Exploring the Therapeutic Potential of Natural Plants in Modulating Molecular and Cellular Pathways Involved in Diabetic Neuropathy: Mechanism and Biochemical Evaluation.Current pharmaceutical design · 2025Review
- Anti-lipidemic and anti-diabetic properties ofIn silico pharmacology · 2025Article
- Article
- Molecular docking analysis of bioactive molecules from herbs with snake venom phospholipase A2.Bioinformation · 2025Article
- Deciphering the Anti-Diabetic Potential of Gymnema Sylvestre Using Integrated Computer-Aided Drug Design and Network Pharmacology.Journal of cellular and molecular medicine · 2025Article
- Synergistic Effects and Mechanisms of Action of Rutin with Conventional Antibiotics AgainstInternational journal of molecular sciences · 2024Article
- The cytoprotective effect ofHeliyon · 2024Article
- Phytofabrication of biocompatible zinc oxide nanoparticle using Gymnema sylvestre and its potent in vitro antibacterial, antibiofilm, and cytotoxicity against human breast cancer cells (MDA-MB-231).Bioprocess and biosystems engineering · 2024Article
- Combined Inositols, α-Lactalbumin, Gymnema Sylvestre and Zinc Improve the Lipid Metabolic Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial.Journal of clinical medicine · 2023Article
- Unlocking the anti-diabetic potential ofFood science & nutrition · 2023Article
- Diet Plus Inositols, α-Lactalbumin andNutrients · 2023Article
- Extraction of gymnemic acid from Gymnema inodorum (Lour.) Decne. leaves and production of dry powder extract using maltodextrin.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.